Given the efficacy of PD-L1 and CTLA4 inhibitors in various cancers, especially in melanoma and certain subsets of breast and cervical cancers, a bispecific antibody targeting both CD274 and CTLA4 has a strong rationale. The gene discussed is CD274; the disease is melanoma.